Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

被引：3
|
作者：
Dees, E. [1 ]
Infante, J. R. [2 ]
Cohen, R. B. [3 ]
O'Neil, B. [1 ]
Burris, H. [2 ]
von Mehren, M. [3 ]
Gray, G. [4 ]
Galvin, K. [5 ]
Manfredi, M. [5 ]
Eton, O. [6 ]
机构：
[1] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Millennium Pharmaceut Inc, Drug Dev, Cambridge, MA USA
[5] Millennium Pharmaceut Inc, Canc Pharmacol, Cambridge, MA USA
[6] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72215-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [41] MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials
    Sells, Todd
    Ecsedy, Jeffrey
    Stroud, Stephen
    Janowick, David
    Hoar, Kara
    Leroy, Patrick
    Wysong, Deborah
    Zhang, Mengkun
    Huck, Jessica
    Silverman, Lee
    Chen, Wei
    Bembenek, Michael
    Claiborne, Christopher
    Manfredi, Mark
    CANCER RESEARCH, 2008, 68 (09)
  • [42] Phase 1 study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States
    Infante, J.
    Dees, E. C.
    Cohen, R. B.
    Burris, H.
    O'Neil, B.
    Murphy, P.
    Lee, Y.
    Pappas, J.
    Ecsedy, J. A.
    Eton, O.
    EJC SUPPLEMENTS, 2008, 6 (12): : 90 - 91
  • [43] Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design (vol 427, pg 19, 2009)
    Dodson, C. A.
    Kosmopoulou, M.
    Richards, M. W.
    Atrash, B.
    Bavetsias, V.
    Blagg, J.
    Bayliss, R.
    BIOCHEMICAL JOURNAL, 2010, 427 : 551 - 551
  • [44] STM-01: Phase I EFFTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
    Dudek, Arkadiusz Z.
    Unal, Imran
    Xie, Hui
    Feldman, Lawrence Eric
    Venepalli, Neeta K.
    Danciu, Oana Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] STM-01: Phase I EffTox study of aurora A kinase inhibitor alisertib (MLN8237) given in combination with selective VEGFR inhibitor pazopanib for therapy of solid tumors.
    Shah, Hirai A.
    Christian, Sonia
    Ahmed, Bilawal
    Chowdhery, Rozina A.
    Venepalli, Neeta K.
    Danciu, Oana Cristina
    Dudek, Arkadiusz Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies
    Siddiqi, Tanya
    Frankel, Paul
    Beumer, Jan H.
    Kiesel, Brian F.
    Christner, Susan
    Ruel, Chris
    Song, Joo Y.
    Chen, Robert
    Kelly, Kevin R.
    Ailawadhi, Sikander
    Kaesberg, Paul
    Popplewell, Leslie
    Puverel, Sandrine
    Piekarz, Richard
    Forman, Stephen J.
    Newman, Edward M.
    LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 309 - 317
  • [47] A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
    Rosenthal, Allison
    Kumar, Shaji
    Hofmeister, Craig
    Laubach, Jacob
    Vij, Ravi
    Dueck, Amylou
    Gano, Katherine
    Stewart, A. Keith
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (02) : 323 - 325
  • [48] Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
    Dees, E. Claire
    Cohen, Roger B.
    von Mehren, Margaret
    Stinchcombe, Thomas E.
    Liu, Hua
    Venkatakrishnan, Karthik
    Manfredi, Mark
    Fingert, Howard
    Burris, Howard A., III
    Infante, Jeffrey R.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4775 - 4784
  • [49] Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
    Hernan Carol
    Ingrid Boehm
    C. Patrick Reynolds
    Min H. Kang
    John M. Maris
    Christopher L. Morton
    Richard Gorlick
    E. Anders Kolb
    Stephen T. Keir
    Jianrong Wu
    Amy E. Wozniak
    Yu Yang
    Mark Manfredi
    Jeffrey Ecsedy
    Jianmin Wang
    Geoffrey Neale
    Peter J. Houghton
    Malcolm A. Smith
    Richard B. Lock
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1291 - 1304
  • [50] Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
    Carol, Hernan
    Boehm, Ingrid
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Morton, Christopher L.
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Wu, Jianrong
    Wozniak, Amy E.
    Yang, Yu
    Manfredi, Mark
    Ecsedy, Jeffrey
    Wang, Jianmin
    Neale, Geoffrey
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1291 - 1304
12345